Last reviewed · How we verify
NCT04340817: FLINC
Fatty Liver Disease in Nordic Countries
Recruiting now
Last updated 13 April 2020
What this trial tests
trial testing Proteomics in Non-Alcoholic Fatty Liver Disease in 634 participants. Currently enrolling.
Timeline
1 September 2017
Primary endpoint
1 September 2025
1 September 2025
1 November 2026
Quick facts
| Lead sponsor | Copenhagen University Hospital, Hvidovre |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 634 |
| Start date | 1 September 2017 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Proteomics
- Transcriptomics
- Genomics
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Sponsor
Copenhagen University Hospital, Hvidovre
Who can join
18 and older, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.
Jara M, Norlin J, Kjær MS, Almholt K, et al · · 2025 · cited 37× · PMID 40691365 · DOI 10.1038/s41591-025-03799-0 -
Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.
Verschuren L, Mak AL, van Koppen A, Özsezen S, et al · · 2024 · cited 36× · PMID 38811591 · DOI 10.1038/s41467-024-48956-0 -
Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.
Kjeldsen SAS, Gluud LL, Werge MP, Pedersen JS, et al · · 2023 · cited 4× · PMID 37953952 · DOI 10.1016/j.isci.2023.108190 -
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis.
Horn P, Norlin J, Almholt K, Viuff BM, et al · · 2024 · cited 3× · PMID 39361025 · DOI 10.7554/elife.95185 -
Identification of ligand and receptor interactions in CKD and MASH through the integration of single cell and spatial transcriptomics.
Moreno J, Gluud LL, Galsgaard ED, Hvid H, et al · · 2024 · cited 3× · PMID 38768139 · DOI 10.1371/journal.pone.0302853 -
Referral Patterns for Patients with Nonalcoholic Fatty Liver Disease.
Rashu EB, Werge MP, Hetland LE, Junker AE, et al · · 2021 · cited 1× · PMID 33494361 · DOI 10.3390/jcm10030404 -
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis
Horn P, Norlin J, Almholt K, Viuff BM, et al · · 2024 · DOI 10.1101/2024.01.03.574043
Verify or expand the search:
- PubMed search for NCT04340817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Proteomics
Trials testing the same drug.
- NCT06544083 — Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood · unknown
- NCT06037759 — Novel Cardiovascular Biomarkers in Patients With Kidney Disease · not yet recruiting
- NCT05181787 — Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics · unknown
- NCT05181774 — Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics · unknown
- NCT06579235 — Explorative Proteomics in Pediatric Neuroborreliosis · active not recruiting
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other Copenhagen University Hospital, Hvidovre trials
Trials by the same sponsor.
- NCT07321379 — Efficacy of Bicarbonate on the Risk of Assisted Delivery in Nulliparous Women With Prolonged Labour · NA · not yet recruiting
- NCT07067060 — Risk of Serious Adverse Events Following Unsupervised vs Supervised Rehabilitation After Knee Arthroplasty · not yet recruiting
- NCT06967324 — GRACE - Graduated Response for Advanced COPD With Enhanced Support · NA · recruiting
- NCT06682260 — Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure · Phase 4 · completed
- NCT06866496 — Optimized Remission in Alcohol-related Liver Cirrhosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04340817 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Copenhagen University Hospital, Hvidovre
- Last refreshed: 13 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04340817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing